receive over the next several years an aggregate of $430 million based on potential future pre-commercialization milestones under our AbbVie and Novartis collaborations, assuming successful clinical trial results for the respective collaboration
additional collaboration product containing a protease inhibitor is co-developed, we would be eligible to receive future milestone payments totaling up to $40 million for similar regulatory and reimbursement approval milestones.Collaboration with NovartisIn February 2012, we entered into a Collaboration and License Agreement with Novartis granting Novartis exclusive, worldwide rights to develop, manufacture and commercialize EDP-239, our lead compound
successful combination therapies for HCV in its various forms;•Collaborate with large pharmaceutical partners to accelerate the development and commercialization of our lead HCV compounds in combination therapies;•Develop independently our own next generation HCV compounds and combination therapies with lower susceptibility to viral resistance;•Continue to leverage and fortify our intellectual property portfolio; and•Invest in research and early-stage development of product candidates for other infectious diseases, including MRSA.Risks Associated with our BusinessOur business is subject to a number of risks of which you should be aware before making an investment decision.
with the lengthy, expensive and uncertain process of clinical development for and regulatory approval of our product candidates; difficulties in commercializing any future product6Table of Contentscandidates and achieving significant market acceptance of them; the potential for unfavorable pricing regulations, third-party reimbursement practices or related healthcare reform initiatives in
the United States and in foreign jurisdictions; and the need to obtain and maintain adequate patent protection for our product candidates and avoid potential infringement of patents or other intellectual property rights of third parties.We have not generated any revenue to date from product sales and have incurred significant operating losses since our inception in 1995
We intend to use the net proceeds from this offering for clinical development of our internal product candidates, new research and development, working capital and other general corporate purposes.Risk factorsYou should read the “Risk Factors” section starting on page 12 of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and stock price.Risks Related to Our BusinessOur financial prospects for the next several years are substantially dependent upon the development and marketing efforts of AbbVie for combination therapies incorporating ABT-450 for the treatment
to generate revenue from Novartis’ development and commercialization of EDP-239, including ones similar to those described in the preceding risk factor regarding our AbbVie collaboration.If Novartis does not perform in the manner we expect or fulfill its responsibilities in a timely manner, or at all, the clinical
product candidates will face competition based on their safety and effectiveness, the timing and scope of the regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position
effective or otherwise does not meet applicable regulatory criteria; and•a future product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all.If we are unable to identify additional compounds suitable for preclinical and clinical development, we may
not be able to obtain sufficient product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our
Any failure of NIAID to continue to fund our contract could have a material adverse effect on our business, results of operations and financial condition.17Table of ContentsRisks Related to Development, Clinical Testing and Regulatory Approval of Our Product CandidatesClinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes.
represent a clinically meaningful improvement in care as compared with other available therapies;•the clinical indications for which any product candidates become approved;•acceptance among physicians, major operators of clinics and patients of any of our product candidates as safe and effective treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the potential and perceived advantages of our product candidates over alternative treatments;•the cost of treatment in relation to alternative treatments;•the availability of adequate reimbursement and pricing by third parties and government authorities;•the continued projected growth of the HCV drug market;•the relative convenience and ease of administration of any combination therapies including our product candidates;•the prevalence and severity of adverse side effects, whether involving the use of our products candidates or similar, competitive products; and•the effectiveness of our or our collaborators’ sales and marketing efforts.If our product candidates are approved and then fail to achieve market acceptance, we would not be able to generate significant revenue.
sale or use of our future products infringe the patent or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided.Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and
to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business.Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to
generally;•the performance of third-party manufacturers of our product candidates, including our collaborators;•the accuracy of our estimates regarding our expenses, future revenue, capital requirements and needs for additional financing;•our expectations regarding the time during which we will be an “emerging growth company” under the JOBS Act;•our financial performance; and•our use of the proceeds from this offering.These forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our